MeiraGTx Holdings

MeiraGTx is a vertically integrated, clinical-stage gene therapy company developing potentially curative treatments for patients with serious diseases. The company's core technology includes a proprietary riboswitch platform that enables precise, small molecule-led control of gene expression, alongside an advanced AAV manufacturing infrastructure. MeiraGTx's clinical pipeline focuses on three main areas: inherited retinal diseases, neurodegenerative diseases, and salivary gland disorders. With in-house GMP manufacturing facilities in London and Ireland, the company maintains end-to-end control over its production processes. MeiraGTx has established significant strategic partnerships, most notably with Johnson & Johnson and Sanofi, to advance its innovative genetic medicines.